Skip to main content
Premium Trial:

Request an Annual Quote

Sysmex, Optim to Establish Digital Medicine Joint Venture

NEW YORK – Japanese diagnostics device firm Sysmex and artificial intelligence company Optim said on Friday  that they have agreed to establish a joint venture aimed at the development and operation of services and platforms for digital medicine.

The two companies formed a business alliance this February and have been collaborating on initiatives to combine Sysmex’s global sales and service network with Optim’s artificial intelligence and data management technologies, including a product it calls Optim Cloud IoT OS. 

Under the newly agreed upon joint venture, the partners said that they plan to develop and test new diagnostic methods that combine image information from gene tests with AI analysis, as well as to use AI for image processing of various data obtained from existing Sysmex analyzers. 

The venture, which they plan to establish in January, will also seek collaborations with pharmaceutical companies, manufacturers of medical devices, and other companies, the firms said. Some discussions are already ongoing with potential pharma and device partners.

Financial terms of the agreement were not disclosed.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.